Blog

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta/X

May 17, 2025, 12:09

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta, Head of the Thoracic Oncology Unit at National institute of Oncology in Mexico, shared a post on X:

“We reported in Nature Communications, this phase 2 trial, the combination of alectinib and bevacizumab (ALEK-B) in patients with advanced ALK rearranged NSCLC from National Cancer Institute, the 12-month PFS rate was 97.1% The 36-month PFS and OS rates were 64.2% and 87.9% respectively.

The ORR was 100%, and the 36-month icPFS rate was 87.8%. Grade 3–4 adverse events occurred in 46.3% of patients, most commonly proteinuria and hepatotoxicity, QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC.”

Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell

Read The Article at Nature Communications.

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

More Posts featuring NSCLC.

Alexandra Garcilazo-Reyes ALK-rearranged NSCLC Andres F. Cardona cancer David Dávila-Dupont Eduardo Rios-Garcia Enrique Caballé-Pérez Graciela Cruz-Rico Jordi Remon Luis Cabrera-Miranda Luis Lara-Mejía Maritza Ramos-Ramírez National Cancer Institute Nature Communications NSCLC OncoDaily Oncology Oscar Arrieta Rafael Rosell

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer